Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)

Key Facts

Status: Forecasted

Posted date: July 11, 2025

Archive date: March 9, 2028

Close date: February 8, 2028

Opportunity ID: 360007

Opportunity number: RFA-FD-25-017

Opportunity category: Discretionary

Agency name: Food and Drug Administration

Agency code: HHS-FDA

Award floor: $0

Award ceiling: $600,000

Cost sharing required: No

Funding Instrument Types
  • Grant
Category of Funding Activity
  • Agriculture
  • Consumer Protection
  • Food and Nutrition
Eligible Applicants
  • Others
Tools
Categories (use these for quoted searches)
  • agency_code:hhs_fda
  • category_of_funding_activity:agriculture
  • category_of_funding_activity:consumer_protection
  • category_of_funding_activity:food_and_nutrition
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:others
  • funding_instrument_type:grant
  • opportunity_category:discretionary
  • status:forecasted
Description

The purpose of this notice of funding opportunity (NOFO) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.

Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
The purpose of this notice of funding opportunity (NOFO) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.
[Forecasted] Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
Forecasted
Food and Drug Administration
Agriculture
Consumer Protection
Food and Nutrition
Grant
Others
2025-07-11